Latest Insider Transactions at Pyxis Oncology, Inc. (PYXS)
This section provides a real-time view of insider transactions for Pyxis Oncology, Inc. (PYXS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Pyxis Oncology, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Pyxis Oncology, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 07
2024
|
Santhosh Palani |
BUY
Grant, award, or other acquisition
|
Direct |
6,000
+50.0%
|
-
|
|
Mar 26
2024
|
John L Flavin |
BUY
Grant, award, or other acquisition
|
Direct |
35,219
+7.86%
|
-
|
|
Mar 26
2024
|
Rachel Humphrey |
BUY
Grant, award, or other acquisition
|
Direct |
38,741
+28.58%
|
-
|
|
Mar 26
2024
|
Jakob Dupont |
BUY
Grant, award, or other acquisition
|
Direct |
38,741
+50.0%
|
-
|
|
Mar 26
2024
|
Freda C Lewis Hall |
BUY
Grant, award, or other acquisition
|
Direct |
35,219
+12.73%
|
-
|
|
Mar 26
2024
|
Darren S Cline |
BUY
Grant, award, or other acquisition
|
Direct |
35,219
+12.29%
|
-
|
|
Mar 26
2024
|
Connealy Pamela Yanchik CFO & COO |
BUY
Grant, award, or other acquisition
|
Direct |
328,710
+22.84%
|
-
|
|
Mar 26
2024
|
Jitendra Wadhane SVP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
131,484
+24.81%
|
-
|
|
Nov 29
2023
|
Connealy Pamela Yanchik CFO & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
36,949
-4.51%
|
$36,949
$1.4 P/Share
|
|
Nov 15
2023
|
Jitendra Wadhane SVP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+13.03%
|
-
|
|
Sep 28
2023
|
Connealy Pamela Yanchik CFO & COO |
BUY
Open market or private purchase
|
Direct |
8,000
+0.97%
|
$8,000
$1.87 P/Share
|
|
Sep 27
2023
|
Connealy Pamela Yanchik CFO & COO |
BUY
Open market or private purchase
|
Direct |
6,426
+0.79%
|
$6,426
$1.85 P/Share
|
|
Sep 27
2023
|
Jitendra Wadhane SVP, Chief Accounting Officer |
BUY
Open market or private purchase
|
Direct |
2,500
+1.09%
|
$2,500
$1.87 P/Share
|
|
Sep 25
2023
|
Jitendra Wadhane SVP, Chief Accounting Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+2.18%
|
$5,000
$1.77 P/Share
|
|
Sep 25
2023
|
Connealy Pamela Yanchik CFO & COO |
BUY
Open market or private purchase
|
Direct |
12,000
+1.47%
|
$12,000
$1.67 P/Share
|
|
Sep 22
2023
|
Connealy Pamela Yanchik CFO & COO |
BUY
Open market or private purchase
|
Direct |
5,000
+0.63%
|
$5,000
$1.74 P/Share
|
|
Sep 22
2023
|
Jitendra Wadhane SVP, Chief Accounting Officer |
BUY
Open market or private purchase
|
Direct |
2,500
+1.13%
|
$2,500
$1.74 P/Share
|
|
Sep 18
2023
|
Lara Sullivan Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
8,541
-0.35%
|
$17,082
$2.1 P/Share
|
|
Sep 14
2023
|
Lara Sullivan Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
100
-0.0%
|
$200
$2.25 P/Share
|
|
Sep 13
2023
|
Lara Sullivan Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
184,742
-7.11%
|
$369,484
$2.13 P/Share
|
|
Sep 13
2023
|
Lara Sullivan Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
3,000
-0.12%
|
$6,000
$2.27 P/Share
|
|
Sep 12
2023
|
Lara Sullivan Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
4,917
-0.19%
|
$9,834
$2.25 P/Share
|
|
Sep 11
2023
|
Lara Sullivan Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
20,000
-0.76%
|
$40,000
$2.27 P/Share
|
|
Sep 07
2023
|
Lara Sullivan Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
469,483
+15.17%
|
-
|
|
Sep 07
2023
|
Jitendra Wadhane SVP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
93,896
+30.7%
|
-
|
|
Sep 07
2023
|
Connealy Pamela Yanchik CFO & COO |
BUY
Grant, award, or other acquisition
|
Direct |
187,793
+19.36%
|
-
|
|
Mar 24
2023
|
Freda C Lewis Hall |
BUY
Grant, award, or other acquisition
|
Direct |
139,355
+40.33%
|
-
|
|
Mar 24
2023
|
Jitendra Wadhane SVP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
74,393
+26.8%
|
-
|
|
Mar 24
2023
|
Jay Feingold Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
209,803
+22.32%
|
-
|
|
Mar 24
2023
|
Connealy Pamela Yanchik CFO & COO |
BUY
Grant, award, or other acquisition
|
Direct |
209,803
+26.09%
|
-
|
|
Mar 24
2023
|
Lara Sullivan Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
703,379
+24.6%
|
-
|
|
Mar 24
2023
|
Thomas Civik |
BUY
Grant, award, or other acquisition
|
Direct |
139,355
+40.33%
|
-
|
|
Mar 24
2023
|
Darren S Cline |
BUY
Grant, award, or other acquisition
|
Direct |
139,355
+39.2%
|
-
|
|
Mar 24
2023
|
John L Flavin |
BUY
Grant, award, or other acquisition
|
Direct |
139,355
+26.95%
|
-
|
|
Mar 24
2023
|
Rachel Humphrey |
BUY
Grant, award, or other acquisition
|
Direct |
58,064
+50.0%
|
-
|
|
Mar 17
2023
|
Pfizer Inc > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
1,811,594
+23.33%
|
$3,623,188
$2.76 P/Share
|
|
Jan 03
2023
|
Connealy Pamela Yanchik CFO & COO |
BUY
Grant, award, or other acquisition
|
Direct |
43,493
+10.16%
|
-
|
|
Jan 03
2023
|
Jay Feingold Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
53,931
+9.39%
|
-
|
|
Jan 03
2023
|
Lara Sullivan Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
95,684
+6.18%
|
-
|
|
Apr 21
2022
|
Mark Chin |
SELL
Open market or private sale
|
Indirect |
1,745,761
-100.0%
|
$5,237,283
$3.05 P/Share
|
|
Apr 14
2022
|
Lara Sullivan Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
315,273
+18.86%
|
-
|
|
Apr 14
2022
|
Jay Feingold Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
115,931
+19.9%
|
-
|
|
Apr 14
2022
|
Connealy Pamela Yanchik CFO & COO |
BUY
Grant, award, or other acquisition
|
Direct |
93,493
+21.52%
|
-
|
|
Mar 31
2022
|
Freda C Lewis Hall |
BUY
Grant, award, or other acquisition
|
Direct |
66,831
+50.0%
|
-
|
|
Mar 31
2022
|
Connealy Pamela Yanchik CFO & COO |
BUY
Grant, award, or other acquisition
|
Direct |
247,524
+50.0%
|
-
|
|
Mar 31
2022
|
Darren S Cline |
BUY
Grant, award, or other acquisition
|
Direct |
66,831
+46.52%
|
-
|
|
Mar 31
2022
|
Mark Chin |
BUY
Grant, award, or other acquisition
|
Direct |
66,831
+50.0%
|
-
|
|
Mar 31
2022
|
Thomas Civik |
BUY
Grant, award, or other acquisition
|
Direct |
66,831
+50.0%
|
-
|
|
Mar 31
2022
|
Lara Sullivan Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
742,574
+41.63%
|
-
|
|
Mar 31
2022
|
Jay Feingold Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
306,930
+46.67%
|
-
|